Condition: Plaque Psoriasis · Sponsor: Zai Lab (Hong Kong), Ltd.
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
This description comes directly from the study's public registry record.
Zai Lab 1102-002 Study Team · 857-971-3465 · Study-ZL-1102-002@zailaboratory.com
Always discuss trial participation with your own doctor first.
| Zai Lab Site 5013 | Phillip, Australian Capital Territory, Australia | Recruiting |
| Zai Lab Site 5021 | Kogarah, New South Wales, Australia | Recruiting |
| Zai Lab Site 5016 | Kotara, New South Wales, Australia | Recruiting |
| Zai Lab Site 5020 | Birtinya, Queensland, Australia | Recruiting |
| Zai Lab Site 5019 | Coorparoo, Queensland, Australia | Recruiting |
| Zai Lab Site 5017 | Woolloongabba, Queensland, Australia | Recruiting |
| Zai Lab Site 5014 | Carlton, Victoria, Australia | Recruiting |
| Zai Lab Site 5015 | Melbourne, Victoria, Australia | Recruiting |
| Zai Lab Site 5002 | Melbourne E., Victoria, Australia | Recruiting |
| Zai Lab Site 5018 | Parkville, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06380907